OncoMatch/Clinical Trials/NCT06056362
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
Is NCT06056362 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for neuroendocrine tumors.
This prospective, single-center, double-blinded study investigates the biodistribution, dosimetry, safety, and diagnostic ability of Al18F-NOTA-LM3 in patients with well-differentiated neuroendocrine tumors. And compares the diagnostic ability of Al18F-NOTA-LM3 with 68Ga-DOTATATE PET/CT and 68Ga-NODAGA-LM3 PET/CT. Clinical management will also be compared using different imaging modalities.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Demographics
Prior therapy
Cannot have received: somatostatin analog
Exception: no long-acting somatostatin analog treatment within 4 weeks
No long-acting somatostatin analog treatment within 4 weeks
Cannot have received: peptide receptor radionuclide therapy
Exception: no PRRT treatment within 8 weeks
No PRRT treatment within 8 weeks
Lab requirements
Kidney function
gfr >= 30 ml/min
Liver function
alt/ast < 5 uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06056362 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior somatostatin analog, peptide receptor radionuclide therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages